Positive Phase II results for investigational checkpoint inhibitor (tiragolumab) in combination with atezolizumab for non-small cell lung cancer (NSCLC)

In the CITYSCAPE trial, tiragolumab plus atezolizumab was superior to atezolizumab alone for overall response rate (31.3% v 16.2%) and median progression-free survival (5.4 months v 3.6 months) (no p values reported), in PD-L1-positive metastatic NSCLC.


Biospace Inc.